Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | BMP1 | P13497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572822 | 0.86 | GABRR1 (0.33) | ADH1BADH1CADH1ABMP1 | |
| SCHEMBL13351128 | 0.83 | ADH1B (0.33) | ADH1BADH1CADH1AMMP2MMP9 | |
| SCHEMBL13350617 | 0.83 | ADH1B (0.33) | ADH1BADH1CADH1AMMP2MMP9 | |
| SCHEMBL14403797 | 0.82 | BMP1 (0.36) | ADH1BADH1CADH1AMMP2MMP9 | |
| SCHEMBL19934631 | 0.81 | BMP1 (0.39) | ADH1BADH1CADH1AMMP2MMP9 | |
| SCHEMBL10442385 | 0.79 | — | — | |
| SCHEMBL23471080 | 0.79 | MMP2 (0.46) | ADH1BADH1CADH1AMMP2MMP9 | |
| SCHEMBL23169884 | 0.79 | BMP1 (0.32) | ADH1BADH1CADH1ABMP1 | |
| SCHEMBL13350764 | 0.79 | HDAC7 (0.38) | ADH1BADH1CADH1AMMP2BMP1 | |
| SCHEMBL23169664 | 0.78 | BMP1 (0.31) | ADH1BADH1CADH1ABMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045480-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | ADH1B 4300/4885ADH1C 4045/4885ADH1A 4101/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | ADH1B 4675/4885ADH1C 4589/4885ADH1A 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.